Evolution Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Evolution Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$51.2K	Buy	+401	New	+$50.1K	0.04%	267

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Evolution Wealth Management's XBI Position: Q1 2026 in Review

Evolution Wealth Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 401 shares worth $51.2K. The stake represents 0.04% of the portfolio and ranks #267 among its holdings.

813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Evolution Wealth Management held 401 shares of State Street SPDR S&P Biotech ETF worth $51.2K as of Q1 2026.
State Street SPDR S&P Biotech ETF was a new Evolution Wealth Management position in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.04% of Evolution Wealth Management's portfolio in Q1 2026, its #267 holding.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Evolution Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.